Introduction: Cardiovascular disease is the principal cause of mortality in the diabetic population. Diabetic-cardiomyopathy increases the risk of heart failure in diabetics independently of coronary artery disease. It is characterized by ventricular dilation, myocardial fibrosis and steatosis. ELIXA, LEADER and SUSTAIN-6 trials have shown decrease in adverse cardiac events with a particular GLP-1 agonist. The aim of this study is to analyze if GLP-1 agonist improves ventricular diastolic function after 6 months of therapy.

Methods: Under IRB approval, a retrospective chart review was performed on 107 patients. (EG). Experimental group of (53) patients received GLP-1agonist and (CG)Control group (54)patients that did not receive GLP-1agonists. Inclusion criteria were DM2, age 40-60 years, 6-months GLP-1 therapy and at least 1 baseline echocardiogram. Statistical analysis were performed for data evaluation.

Results: From the population studied, female was the most prevalent gender with 58.8%(63), the mean-age was 57±6.7y/o, and the most common ethnicity Caucasian 67.2%(72). The most prevalent GLP-1 used were; Liraglutide(26.5%), Exenatide(11.2%), Dulaglutide(6.8%) and Albiglutide(1.1%). When comparing echocardiogram parameters, we found; the ejection fraction in the EG was 58±12% at baseline vs. 57±8% at six-month, Lateral-Mitral E/e’ ratio 10.3±3.8 vs. 11.35±5.2, Septal-Mitral E/e’ 13.4±5.4 vs. 14.3±6.3 and Mitral E/a’ 1.1±0.5 vs. 1.07±0.5. When analyzing the (CG) echocardiogram parameters, we found that the Ejection fraction at baseline was 60±8% vs. 58±9% at six months, Lateral-Mitral E/e’ 11.15±5.4 vs. 11.84±5.5, Septal-Mitral E/e’ 14.5±7.2 vs. 15.73±6.6, and Mitral E/a’ 0.98±0.46 vs. 1.09±0.8. No statistically significant difference was found.

Conclusions: This analysis was unable to show that GLP-1 agonists improve diastolic function at the time frame studied. Studies with larger sample and longer follow-up should be performed for better understand these findings.


S.S. Mahapatra: None. C. Milla-Matute: None. C.V. Villabona: None. L. Caraballo: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at